Abstracts tagged "biopsy"

Abstract Number: 738 • 2019 ACR/ARP Annual Meeting
Systemic Sclerosis Myocarditis Has Unique Clinical, Histological and Prognostic Features: Comparative Analysis Between Patients with Endomyocardial Biopsy-proven Myocarditis
Giacomo De Luca¹, Silvia Bosello ², Corrado Campochiaro ¹, Silvia Sartorelli ³, Giovanni Peretto ⁴, Simone Sala ⁵, Giovanni Canestrari ², Gaetano Thiene ⁶, Cristina Basso ⁶, Paolo Della Bella ⁴, Elisa Gremese ⁷ and Lorenzo Dagna ¹, ¹Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy, ²Rheumathology Division, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ³Vita-Salute San Raffaele University, IRCCS San Raffaele Hospital, Milan, Italy, ⁴Department of Cardiac Electrophysiology and Arrhythmology, IRCCS San Raffaele Hospital, Milan, Italy, ⁵Department of Cardiac Electrophysiology and Arrhythmology, IRCCS San Raffaele Hospital, Mialn, Italy, ⁶Cardiovascular Pathology Unit, Department of Cardiac, Thoracic and Vascular Sciences, University and Hospital of Padua, Padua, Italy, ⁷Division of Rheumatology - Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
Background/Purpose: Myocarditis is a life-threatening inflammatory disease increasingly reported in Systemic Sclerosis(SSc); the histological, clinical and prognostic features of SSc-myocardits have not been elucidated yet.…
Abstract Number: 2688 • 2019 ACR/ARP Annual Meeting
Comparisons of Strategies for Diagnostic Assessment in Giant Cell Arteritis: Results from an International Observational Cohort
K Bates Gribbons¹, Cristina Ponte ², Anthea Craven ³, Joanna Robson ⁴, Ravi Suppiah ⁵, Raashid Luqmani ³, Richard Watts ⁶, Peter Merkel ⁷ and Peter C. Grayson ⁸, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²Department of Rheumatology, Hospital de Santa Maria, Lisbon, Portugal, ³University of Oxford, Oxford, United Kingdom, ⁴Faculty of Health and Applied Sciences, University of the West of England, Bristol, United Kingdom, ⁵Department of Rheumatology, Auckland District Health Board, Auckland, New Zealand, ⁶Norwich Medical School, University of East Anglia, Norwich, United Kingdom, ⁷University of Pennsylvania, Philadelphia, PA, ⁸National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of the National Institutes of Health, Bethesda, MD, Bethesda, MD
Background/Purpose: Diagnostic assessment in giant cell arteritis (GCA) is rapidly changing as large-vessel (LV) involvement becomes increasingly recognized and non-invasive vascular imaging techniques become more…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].